PANASONIC
Panasonic Corporation today announced that the company, in collaboration with the Japan Textile Products Quality Technology Center, has verified the inhibitory effect of nanoe™ on novel coronavirus adhering in a 24 m3 test space. This is the first time in the world that the inhibitory effect on adhered novel coronavirus has been verified in a test space almost as large as a daily living space.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220224005542/en/
nanoe™ is a technology that collects invisible moisture in the air and applies a high voltage to it to produce “hydroxyl radicals contained in water”. Hydroxyl radicals inhibit the growth of pollutants such as bacteria and viruses. They are characterized by being strongly oxidative and highly reactive, hence a short life span. Contained in tiny water particles, nanoe™ has a long lifespan and can spread around the space in a room. It has an inhibitory effect on both airborne and adhered substances.
The mutation of the amino acid in the spike protein has caused new variant strains with different infectivity, transmissibility, and antigenicity such as the increased binding capacity to cells and reduced binding to neutralizing antibodies. Consequently, the global spread of the novel coronavirus shows no sign of abating. Research is underway to identify the properties of the current dominant Omicron strain, but the increase in secondary infections in households and other factors suggest that its infectivity has increased compared to conventional strains, and further infection prevention measures are crucial.
Concerning the nanoe™ technology, Panasonic verified their inhibitory effect on the novel coronavirus (SARS-CoV-2)*2 in July 2020 and its inhibitory effect on four novel coronavirus variants*3 in November 2021. The results of the previous tests were conducted in a small test space of 45-litres.
Therefore, Panasonic carried out a comparative experiment in a 24 m3 test space to compare virus titers with and without exposure to nanoe™. A piece of gauze saturated with the Delta strain of the novel coronavirus was exposed to nanoe™ for 8 hours and the inhibitory effect of more than 99% was confirmed. Note that the verification results are based on a test in a closed test environment and not in space actually in use.
Panasonic will continue to pursue the potential of nanoe™ technology and contribute to society by providing safer and more secure spaces.
・ For reference
Testing the inhibitory effect of nanoe technology confirmed on the adhered novel coronavirus Delta variant (SARS-CoV-2) in a test space of approximately 24m3
・ Overview
A comparative verification was conducted in a 24m3 test space containing the adhered novel coronavirus Delta variant (SARS-CoV-2)
・ Results
The reduction in virus infection titer of more than 99% against the adhered novel coronavirus Delta variant (SARS-CoV-2) with the nanoe™technology was also verified in a 24 m3 test space.
Note: This verification was designed to generate basic research data on the effects of nanoe™ on the novel coronavirus in laboratory conditions different from those found in living spaces.
・ Results data
Test subject |
Time |
Inhibition rate |
Adhered novel coronavirus Delta variant (SARS-CoV-2) |
8 hours |
99.8% |
・ Methodology and data
Organisation :Japan Textile Products Quality and Technology Center (QTEC)
Subject :Adhered novel coronavirus Delta variant (SARS-CoV-2)
Device :nanoe™ device
Method:
► In a test space of 24m3 , (2700mm x 3640mm x 2450mm) place a piece of gauze saturated with the virus solution at a position 1.5m from nanoe™ generator and 1.2m from the floor, and exposed to nanoe™ (diffused into the test space by airflow from a blower installed on the wall).*4
► The virus infection titer is measured and the inhibition rate is calculated *5
・ Principle of the generation of hydroxyl radicals
The atomization electrode is cooled by a Peltier element, which condenses moisture in the air to create water. Afterwards, a high voltage is applied across the atomization and the counter electrodes to generate “hydroxyl radicals contained in water” of approx. 5 to 20 nm in size.
*1 Regarding ion emission type air cleaning technology (As of March 1, 2022, surveyed by Panasonic)
*2 Verification of the inhibitory effect of hydroxyl radicals contained in water on the novel coronavirus (SARS-CoV-2) (Released in July 2020)
*3 Verification of the inhibitory effect of the nanoe technology on four feared mutant strains of the new coronavirus (released in November 2021). The titer of the new coronavirus and the four mutant strains showed the same decreasing trend regardless of the strain. The same results can be expected for mutant strains that may emerge in the future if tested under the same conditions in 45L.
*4 Based on "Test method for evaluating air purifiers' performance in inhibiting viruses adhering indoors (established on July 4, 2011)" specified by the Japan Electrical Manufacturers' Association
*5 Calculated by Panasonic
About Panasonic
Panasonic Corporation is a global leader developing innovative technologies and solutions for wide-ranging applications in the consumer electronics, housing, automotive, and B2B sectors. The company, which celebrated its 100th
anniversary in 2018, operates 522 subsidiaries and 69 associated companies worldwide and reported consolidated net sales of 6,698.8 billion yen for the year ended March 31, 2021. Committed to pursuing new value through collaborative innovation, the company uses its technologies to create a better life and a better world for customers. Learn more about Panasonic: https://www.panasonic.com/global
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20220224005542/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom